Helsinki, Finland; Naples, Italy – 21 August 2026 – Valo Therapeutics Group (“Valo Therapeutics”), a clinical-stage biotechnology company developing novel immunotherapies for cancer, announced the appointment of Carlos de Sousa, MD, MBA, as Chief Executive Officer of Valo Therapeutics Group.

Carlos is a senior biopharmaceutical executive and business leader with extensive international experience across biotechnology, pharmaceuticals, oncology, immunotherapy, business development, licensing, mergers and acquisitions, corporate strategy and medical affairs.

Throughout his career, Carlos has held CEO, President, Chief Business Officer and other senior leadership roles across public and private life sciences companies, including Ultimovacs, Immunicum, Zealand Pharma, Nycomed/Takeda, Novartis and Pfizer. He has led organizations through strategic growth, fundraising, public-market listings, clinical development programmes, partnerships and complex corporate transactions across Europe, North America and international markets.

A physician by training and an Executive MBA graduate of NYU Stern School of Business, Carlos combines scientific and medical expertise with extensive commercial and strategic leadership experience. His career spans multiple therapeutic areas, including oncology, respiratory disease, central nervous system disorders, gastroenterology and dermatology, with experience ranging from early-stage clinical development through global commercialization.

Carlos also brings a strong track record of building high-performing teams, leading multicultural organizations and identifying and executing strategic opportunities within the global life sciences sector.

Carlos de Sousa, CEO of Valo Therapeutics Group, commented:

“I am delighted to join Valo Therapeutics at an important stage in the Company’s development. Valo has built a highly innovative immuno-oncology platform with the potential to generate meaningful benefit for patients. I look forward to working closely with the Board, management team, employees, clinical partners and investors to advance our clinical programmes, strengthen the Company’s strategic position and unlock the full potential of Valo’s technology.”

The appointment further strengthens Valo Therapeutics’ leadership as the Company continues to advance its clinical development activities and explores strategic opportunities to accelerate the development and commercialization of its immunotherapy platform.

About Valo Therapeutics

Valo Therapeutics is a clinical-stage biotechnology company developing novel immunotherapies designed to generate strong and durable anti-tumour immune responses. The Company’s lead clinical programme is based on its proprietary PeptiCRAd technology, which combines oncolytic adenoviruses with tumour-associated peptides to stimulate systemic, tumour-specific immune responses.